partnering

News

Pieris wields axe after losing AZ as partner for elarekibep

AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strateg

News

Paul Biondi of Flagship's Pioneering Medicines

Pfizer inks $7bn strategic level R&D deal with Flagship

Pfizer has just made venture capital firm Flagship Pioneering a key component of its R&D engine, signing a deal worth up to $7 billion that will allow it to harvest ne

News

Roche eyeing $7bn deal to buy Roivant drug; report

Roche is reported to be in the final stages of negotiating a deal with Roivant for an inflammatory bowel disease (IBD) candidate that could be worth up to $7 billion, acco

News

TIGIT underwhelms again as Novartis ducks out

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered

News

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

Johnson & Johnson has bolstered its oncology pipeline by licensing a drug from Nanobiotix designed to enhance the effectiveness of radiotherapy for solid tumours.

News

Eiger wields axe as FDA sets high bar for hepatitis drug

Eiger BioPharmaceuticals has said it will cut staffing numbers by 25% and refocus its R&D activities on metabolic diseases, after the FDA said it would need a new stud

Pieris wields axe after losing AZ as partner for elarekibep

Pfizer inks $7bn strategic level R&D deal with Flagship

Roche eyeing $7bn deal to buy Roivant drug; report

TIGIT underwhelms again as Novartis ducks out

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

Eiger wields axe as FDA sets high bar for hepatitis drug

Immunovant's thyroid eye disease drug flunks pivotal trials

Using AI-driven synthetic personas to take your insights fur...

partnering

Editor's Picks